Vicki Moore, PhD

Contributing Writer https://www.oncologynurseadvisor.com

Vicki Moore, PhD, is a freelance medical writer for Hematology Advisor. Vicki received her PhD in biology from Arizona State University, where her research emphasized molecular biology, biochemistry, and metabolic engineering. She also has experience with predictive analytics and is intrigued by its applications to medicine. Vicki has been a medical writer, focusing on areas of hematology and oncology, among other specialties, since late 2017. You can find her on Linkedin at linkedin.com/in/vicki-moore-93950913

All articles by Vicki Moore, PhD

Multiple Myeloma

Doublet vs Triplet Bortezomib-Based Therapy for Renal Recovery in Myeloma Cast Nephropathy

Vicki Moore, PhD

July 15, 2020

For patients with initial myeloma cast nephropathy, renal response rates did not significantly vary after doublet vs triplet bortezomib-based treatments.

Lymphoma

Selinexor in Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Vicki Moore, PhD

July 14, 2020

A clinical trial suggests efficacy and a manageable adverse event profile with selinexor for the treatment of relapsed or refractory DLBCL.

Leukemia

Ofatumumab Plus Hyper-CVAD for Newly Diagnosed (Ph)-Negative, CD20-Positive B-Cell ALL

Vicki Moore, PhD

July 14, 2020

Combined ofatumumab and hyper-CVAD is a safe and active treatment for adult patients with (Ph)-negative, CD20-positive B-cell ALL.

Nurse tending patient in intensive care.

Myeloproliferative Neoplasms

Infection Risk for Patients With Myeloproliferative Neoplasms

Vicki Moore, PhD

July 9, 2020

Matched cohort study showed risk greatest for those with primary myelofibrosis, but still high for those with polycythemia vera and essential thrombocythemia.

Some therapies have been linked to cognitive effects.

Hematologic Cancers

Cognitive Impairment Affects Survival Outcomes in Geriatric Patients Undergoing Allogeneic HCT

Vicki Moore, PhD

July 7, 2020

An analysis of more than 300 patients with hematologic cancer found that cognitive impairment had a negative effect on outcomes, whereas age and IADLs did not.

General Oncology

Age, Residence, Other Factors Associated With Palliative Care Consultations in Patients With Advanced Cancer

Vicki Moore, PhD

June 25, 2020

Several factors were found to affect whether patients with cancer received a palliative care consultation at a tertiary care center.

General Oncology

Bodyweight-Based Dosing of Nivolumab Results in Wastage

Vicki Moore, PhD

June 23, 2020

A review of practices prior to a change in nivolumab dosing demonstrated that bodyweight dosing resulted in a 6.1% rate of wastage at a significant cost compared with a fixed dose of 240 mg per dose.

Immunotherapy may be effective for some patients with NSCLC as a second-line treatment, but it’s unc

Leukemia

Results of GO-CLLEAR Study in Patients With Chronic Lymphocytic Leukemia

Vicki Moore, PhD

June 17, 2020

Investigators compare efficacy and safety of obinutuzumab/chlorambucil, rituximab/ chlorambucil, and rituximab/bendamustine as frontline CLL treatments.

Side-Effect Management

Genetic Polymorphisms: Understanding Their Relationship With Pain and Treatment in Patients With Cancer

Vicki Moore, PhD

June 17, 2020

A discussion on the genetic influence of single nucleotide polymorphisms on cancer pain and their potential to assist pain management in patients with cancer.